Analysts Raise Amgen Price Targets Amid Portfolio Strength and Financial Visibility

In the past week, several investment banks have raised their price targets on Amgen Inc. (NASDAQ: AMGN), pointing to what they describe as the company’s robust portfolio and positive regulatory momentum.

Analyst Upgrades Reinforce Confidence

Cantor Fitzgerald lifted its price target on Amgen to $440 from $400, maintaining its position and highlighting the strength of the company’s diversified portfolio. This upgrade was reported on October 8, 2026. Investors.com and related outlets referenced this revision, underlining growing confidence in Amgen’s strategic positioning and commercial outlook.

Meanwhile, Truist Securities raised its target to $380 from $362 on October 7, 2026, while maintaining a Hold rating. The increase signals appreciation for Amgen’s pipeline progress, though the firm stopped short of shifting to a more bullish stance.

These target revisions reflect a broader sentiment among investment analysts that Amgen’s recent developments—particularly around regulatory approvals and product innovation—are strengthening its valuations trajectory.

Regulatory Evolution Adds Momentum

On the regulatory front, the U.S. Food and Drug Administration approved a reduced monitoring time for the first two doses of IMDELLTRA®, Amgen’s treatment for extensive-stage small cell lung cancer. This approval, announced recently, may ease treatment protocols and bolster adoption. Investing.com noted the FDA update and its relevance for IMDELLTRA’s wider clinical use.

While analyst upgrades often follow corporate developments such as regulatory shifts, none of the published commentary directly ties the recent target increases to this FDA action. That said, the concurrence of both developments strengthens the perception of forward momentum for Amgen.

Stock Performance Without Precise Causal Links

Amgen’s most recently verified closing price is $432.49, representing a 1.23% decline as of October 16, 2026. This figure is confirmed and should be used in analyses of current valuation. It remains unclear whether the analyst target changes or regulatory developments directly influenced the stock’s intraday or near-term price trajectory.

Notably, Amgen is a key component of the Dow Jones Industrial Average, which typically amplifies investor attention on its moves, though attributions of causation require careful linkage.

What Investors Should Watch

• Analyst sentiment remains cautiously optimistic, supported by steady pipeline innovation and regulatory approvals such as the IMDELLTRA® label update.
• Watch for upcoming earnings or pipeline announcements that may provide clearer connections between analyst revisions and actual business performance.
• Amgen’s strategic diversified portfolio, from oncology to rare disease therapies, continues to underpin analyst confidence—evident in the recent price target increases.

In summary, Amgen has received positive attention from investment banks this week, with raised price targets signaling confidence backed by recent developments. Investors should monitor how these expectations align with upcoming disclosures and whether regulatory tailwinds translate into measurable financial gains.